Other Work

NOW Comments to the FDA about the Availability of Demographic Subgroup Data

Because some companies have been reticent to invest in pre-market or post-market clinical trials on diverse populations, it is imperative that the FDA be firm in their directive in this area, and enforce the requirement for diversity and subgroup analyses.